BMRN - BioMarin Pharmaceutical Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
-1.52 (-1.85%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close82.36
Bid0.00 x 1000
Ask0.00 x 1000
Day's Range80.55 - 83.03
52 Week Range79.13 - 106.74
Avg. Volume1,324,360
Market Cap14.476B
Beta (3Y Monthly)1.32
PE Ratio (TTM)N/A
EPS (TTM)-0.50
Earnings DateJul 31, 2019 - Aug 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est119.91
Trade prices are not sourced from all markets
  • Chicago biotech sues Third Rock, bluebird bio CEO over gene therapy license
    American City Business Journals3 days ago

    Chicago biotech sues Third Rock, bluebird bio CEO over gene therapy license

    Errant Gene Therapeutics claims in a new lawsuit that local venture capital firm Third Rock Ventures and bluebird bio CEO Nick Leschly worked to hinder its drug development efforts so it could obtain a key part of its intellectual property.

  • 9 major Bay Area tech employers pay a typical worker more than $200K per year
    American City Business Journals5 days ago

    9 major Bay Area tech employers pay a typical worker more than $200K per year

    Large Bay Area tech employers that pay a typical employee more than $200,000 per year include the typical suspects like Google parent Alphabet Inc., Facebook and Netflix. But several companies that are lesser-known outside Silicon Valley also pay top dollar for talent.

  • 'Something worth doing': How a biotech entrepreneur grew a 700-person company and is conquering rare diseases
    American City Business Journals6 days ago

    'Something worth doing': How a biotech entrepreneur grew a 700-person company and is conquering rare diseases

    Emil Kakkis launched Ultragenyx Pharmaceutical in Novato and the EveryLife Foundation for Rare Diseases, lobbying for legislative changes to make it easier to develop rare disease drugs.

  • Here is What Hedge Funds Think About BioMarin Pharmaceutical Inc. (BMRN)
    Insider Monkey6 days ago

    Here is What Hedge Funds Think About BioMarin Pharmaceutical Inc. (BMRN)

    Before we spend countless hours researching a company, we'd like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]

  • Should BioMarin Pharmaceutical (NASDAQ:BMRN) Be Disappointed With Their 32% Profit?
    Simply Wall St.7 days ago

    Should BioMarin Pharmaceutical (NASDAQ:BMRN) Be Disappointed With Their 32% Profit?

    It hasn't been the best quarter for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shareholders, since the share price has...

  • Markit7 days ago

    See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

    Biomarin Pharmaceutical Inc NASDAQ/NGS:BMRNView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for BMRN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding BMRN totaled $4.26 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • 3 Top Growth Stocks to Buy in June
    Motley Fool8 days ago

    3 Top Growth Stocks to Buy in June

    If you have some cash to put to work, you'll want to take a look at these three companies from the tech, drug, and industrial sectors.

  • BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady
    Zacks11 days ago

    BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady

    BioMarin's (BMRN) Vimizim gains an NMPA nod in China for addressing patients suffering Morquio A syndrome, an ultra-rare genetic condition.

  • PR Newswire12 days ago

    BioMarin to Participate in Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11 in Rancho Palos Verdes, CA

    SAN RAFAEL, Calif. , June 5, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Henry Fuchs , M.D., President, Worldwide Research & Development, will present at the Goldman ...

  • PR Newswire13 days ago

    BioMarin Announces Approval of Vimizim® (elosulfase alfa) in China for Treatment of Morquio A Syndrome

    SAN RAFAEL, Calif., June 4, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) announced today that Vimizim® (elosulfase alfa) has been approved by the National Medical Products Administration (NMPA) for the treatment of patients with mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome.

  • 5 Best-Rated Stocks To Buy Amid Selloff
    TipRanks15 days ago

    5 Best-Rated Stocks To Buy Amid Selloff

    Shares have taken a beating recently. In fact, President Trump declared trade war on a new front Thursday, proposing a 5% tariff on all goods imported from Mexico, beginning June 10. In lieu of agreement between the U.S. and its neighbor to the south, the tariff would gradually increase to 25% by October. That’s on top of continued tension with China.This continued global economic uncertainty sent investors looking for security in bonds. Short-term rates moved so low on Wednesday that the yield on 3-month bills T-bills was 14 basis points below 10-year notes, which is a level of inversion that hasn’t been experienced since the Financial Crisis. Bond investors are not always right, obviously, but an inverted yield curve is generally viewed as a signal that a recession could materialize in the next year or so. However not all is lost. There are still plenty of compelling investing opportunities out there. You just have to know where to look. Here we delve into the Street’s best-rated trending stocks right now. In other words, these are five of the stocks that have received the most buy ratings from analysts over the last seven days. View Trending Stocks detailSo what is driving this particularly bullish Street sentiment? Let’s take a closer look at these five top stocks: 1\. BioMarin Pharmaceutical Inc (BMRN – Research Report) BioMarin is buzzing right now. This pharma company has just received 11 back-to-back analyst buy ratings in just the last week. Analysts applauded a critical update from BioMarin’s Ph. I/II clinical study of valrox in patients with hemophilia A as well as initial data from the Ph. III study.Valrox is BioMarin’s gene therapy for hemophilia A, which management anticipates should receive regulatory approval in the third quarter of 2020. Working backwards, this would suggest an application submission in Q1’20. “We expect these data to support accelerated approval, and drive adoption” writes top-rated Cowen & Co analyst Phil Nadeau on May 28. He has a $150 price target on shares, indicating significant upside potential of 82%. “While valrox's launch trajectory remains uncertain, there is little question that Hem A is a large market and BioMarin estimates that overall there are 117K hemophilia A patients in its territories with 18K in North America alone” points out the analyst.This means that even modest penetration with a price point around $2MM would represent significant revenue, as ~$1B in sales could be achieved for every 500 adult patients treated. “Therefore valrox should soon become a growth driver for BioMarin” sums up Nadeau. See what other Top Analysts are saying about BMRN. 2\. Dollar General Corp (DG – Research Report) Leading US discount retailer Dollar General has rallied 5% in the last five days, bringing its total year-to-date gain to an impressive 18%. The company has just reported stellar results for the first quarter with both comps and margins modestly above expectations. The result: eight consecutive buy ratings from the Street. “We remain buyers given our bullishness on DG’s defensive growth characteristics” writes RBC Capital analyst Scot Ciccarelli. “While mix and transportation costs continue to weigh on GMs and investments in initiatives like DG Fresh and Fast Track will pressure SG&A this year, these strategies (and several others) are helping drive solid sales growth” explains the analyst. While the year is clearly off to a good start, he believes management maintained guidance given the absorption of recent tariff increases, ongoing tariff uncertainty and 3/4 of the year still in front of us. Nonetheless, Ciccarelli still decides to boost his price target from $133 to $139 (9% upside potential). However, the highest price target comes from Buckingham Research’s Bob Summers. Post-earnings the analyst boosted his price target considerably, from $125 to $152 (19% upside potential) citing the ‘powerful combination’ of a strong quarter and beneficial macro backdrop for discount retailers. See what other Top Analysts are saying about DG. 3\. Inc (CRM – Research Report) Salesforce calls itself the world's 1 customer relationship management platform. And now it's crunch-time for the stock. On June 4, CRM will release its earnings results for the fiscal first quarter. Ahead of the print, analysts are optimistic about CRM’s outlook. Indeed five analysts have reiterated their buy ratings on the stock in the last week.Moness analyst Brian White sees prices spiking 29% to $195 in the coming months. He tells investors: “In a volatile market environment driven by growing trade tensions with China and now decisively spilling over into parts of the tech world, we believe SaaS vendors such as Salesforce remain attractive with a subscription-based model and strong secular cloud trends.” As for earnings, White is predicting strong 1Q:FY20 revenue forecast of $3.683 billion (up 23% YoY; Street is at $3.682 billion) and non-GAAP EPS estimate of $0.61 (Street is also at $0.61). Looking into 2Q:FY20, he is projecting sales of $3.921 billion with non-GAAP EPS rising to $0.69.A similarly bullish perspective comes from Piper Jaffray’s Alex Zukin: “We view CRM as the most attractive risk/reward in our coverage universe today.” Following positive checks with corporate tech buyers, he writes “Our checks suggest the company delivered results at or near internal plan” for the fiscal first-quarter. Plus CRM shares have dropped 8% in May- underperformed other software stocks in the analyst’s coverage universe. That makes now an appealing time to buy-in. As a result, Zukin reiterates his Salesforce buy rating and $180 price target (19% upside potential). See what other Top Analysts are saying about CRM. 4\. Apple Inc (AAPL – Research Report) Trade tensions have wreaked havoc with Apple- sending prices plunging 13% in May. But that has done little to dent the Street’s enthusiasm for Apple stock. Indeed, in the last seven days, four analysts have reiterated their AAPL Buy ratings. One of these analysts is five-star Tigress Financial analyst Ivan Feinseth. “We reiterate our Strong Buy rating on AAPL as it continues to create value from its ecosystem with the launch of its key Services initiatives and view the recent U.S.-China trade-related weakness as a major buying opportunity” advises Feinseth. According to the analyst, AAPL’s Services business segment continues to emerge as one of the company’s future drivers of growth and profitability. That’s with new initiatives like a gaming platform, a credit card, a news service, and a video streaming service.These should provide more continuity to its ecosystem and further monetize the close to one billion iPhone user base, says Feinseth. He doesn’t offer a price target, but he does write: “We believe significant upside in the shares exists from current levels.” The stock is on both the firm’s Research Focus List and its Focus Opportunity Portfolio. Meanwhile Webush’s Daniel Ives delves further into the US-China impact on Apple. He has a buy rating on the stock with a $235 price target (34% upside potential). “We continue to strongly believe that for a company that employees over 1 million Chinese workers with its flagship Foxconn factory and is a major strategic player within the China technology ecosystem that from a supply chain perspective Apple will not have major roadblocks ahead despite the loud noise” writes the analyst. In fact, Ives believes the biggest risk comes from pro-China sentiment negatively impacting demand, but argues that this situation is currently contained at around 3% to 5% of Chinese iPhone sales. “Taking a step back, we ultimately believe there is a low likelihood that Apple and its iPhones feel the brunt of the tariffs given its strategic importance domestically as well as Cook’s ability to navigate these issues in the past” he concludes. See what other Top Analysts are saying about AAPL. 5\. Marvell Technology Group (MRVL – Research Report) Shares in semiconductor manufacturing stock Marvell have exploded by 38% year-to-date. And now the company has just released its first quarter results. MRVL’s F1Q20 results were better than expected, but F2Q20 guidance was below expectations. The report reveals soft storage demand, although MRVL continues to expect a recovery in C2H20.However strong 5G momentum is keeping analysts and investors on-side. Most notably, MRVL announced two new 5G wireless base station design wins, which together are expected to increase MRVL's content per a base station by ~$500. As a result, six analysts have published buy ratings on Marvell in the last seven days, vs just 1 hold rating. “With two new 5G wireless base station design wins announced (first win generating rev in F4Q20) and a continued focus on high growth end markets with the Aquantia and Avera acquisitions and the divestiture of its WiFi business, we maintain our Buy and $28 PT” cheers Needham’s Quinn Bolton. From current levels that works out at 26% upside potential. Rosenblatt’s Hans Mosesmann backs up Bolton’s estimates. He has just ramped up his price target from $24 to $28, explaining: “All in, we believe Marvell’s strategic positioning has improved at a much faster than expected rate and as a result, we are increasing our PT to $28 from $24.” See what other Top Analysts are saying about MRVL.

  • Motley Fool17 days ago

    Is the $2.1 Million Price Tag for Novartis' Zolgensma Ridiculous?

    The sky-high price of this revolutionary new gene therapy may not be as crazy as it seems.

  • BioMarin Announces Data on Hemophilia Candidate, Shares Fall
    Zacks19 days ago

    BioMarin Announces Data on Hemophilia Candidate, Shares Fall

    BioMarin (BMRN) announces significant reduction in annual bleed rate in phase III study evaluating gene therapy, valoctocogene roxaparvovec, in hemophilia A patients. However, investors are skeptical.

  • Biotech Stock Roundup: AMGN's Nuevolution Buyout, CELG, INCY Drugs' Label Expansion
    Zacks19 days ago

    Biotech Stock Roundup: AMGN's Nuevolution Buyout, CELG, INCY Drugs' Label Expansion

    Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.

  • How BioMarin May Revolutionize the Hemophilia Treatment Market
    Motley Fool20 days ago

    How BioMarin May Revolutionize the Hemophilia Treatment Market

    The latest trial results for its hemophilia A gene therapy suggest it may eliminate or significantly reduce the need for weekly infusions.

  • A hemophilia patient hero at zero, BioMarin to seek FDA OK for gene therapy. But will the effect last?
    American City Business Journals20 days ago

    A hemophilia patient hero at zero, BioMarin to seek FDA OK for gene therapy. But will the effect last?

    BioMarin's gene therapy for hemophilia A dropped potentially life-threatening bleeding events from more than a dozen to zero.

  • What Happened in the Stock Market Today
    Motley Fool20 days ago

    What Happened in the Stock Market Today

    Global Payments and Total Systems Services announced they plan to merge, and BioMarin reported results from a gene therapy trial.

  • Barrons.com20 days ago

    BioMarin’s 2019 Stock Gains Erased After Release of Gene Therapy Data

    Shares fell 5.2% on Tuesday, wiping out its gains for the year, after the company reported data on two studies of a gene therapy it is developing to treat hemophilia A.

  • This Biotech Had Positive Data In Gene Therapy — But It Wasn't Enough
    Investor's Business Daily20 days ago

    This Biotech Had Positive Data In Gene Therapy — But It Wasn't Enough

    BioMarin Pharmaceutical stock dipped Tuesday after its gene therapy results underwhelmed investors and raised "more questions" regarding hemophilia A treatment, an analyst said in a note.

  • Reuters20 days ago

    BioMarin's hemophilia gene therapy data shows promise

    BioMarin Pharmaceutical Inc said on Tuesday data from an early study of its gene therapy for hemophilia A appeared to show blood clotting protein levels were stable, three years after patients were given a one-time infusion of the drug. The company is expected to price the drug, valoctocogene roxaparvovec, at over $1 million for a single dose, but investors are focused on whether the effects of the treatment will last long enough to command such a high price. The data suggest the value of the drug is equivalent to five-year cost of standard treatment for hemophilia, which the company said averaged about $400,000 for adults, Chief Executive Officer Jean-Jacques Bienaime told analysts on a call.

  • Reuters20 days ago

    BioMarin says hemophilia gene therapy meets certain criteria in late-stage trial

    BioMarin Pharmaceutical Inc said on Tuesday data from a group of patients in a late-stage study of its gene therapy for a bleeding disorder showed the drug met certain criteria, which will help it to apply ...

  • PR Newswire20 days ago

    BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe

    Timing of Regulatory Submissions to Be Determined in 3Q 2019 Conference Call and Webcast to be Held Tuesday, May 28, 2019 at 8:00 AM Eastern SAN RAFAEL, Calif. , May 28, 2019 /PRNewswire/ -- BioMarin Pharmaceutical ...

  • PR Newswire20 days ago

    BioMarin Provides 3 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A

    "These data confirm that valoctocogene roxaparvovec has the potential to profoundly impact the lives of people with severe hemophilia A through a sustained reduction in bleeds and factor VIII usage," said Hank Fuchs, M.D., President, Global Research and Development at BioMarin.  "Importantly, we've now observed that maintenance of factor expression is a function of expression level and time.

  • PR Newswire21 days ago

    BioMarin to Host Conference Call Tuesday, May 28, 2019 to Provide a Valoctocogene Roxaparvovec Phase 2 and Phase 3 Update

    SAN RAFAEL, Calif. , May 27, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), today announced that management will host a conference call and webcast on Tuesday, May 28 at 8:00am ET to ...

  • 3 Big Biotech Stocks That Warren Buffett Might Like
    Motley Fool22 days ago

    3 Big Biotech Stocks That Warren Buffett Might Like

    There's at least one thing about these biotechs that the Oracle of Omaha should find especially appealing.